Doripenem Monohydrate, also known as S-4661 and Finibax, is a beta-lactam class drug used for bacterial infections with ultra-broad antibiotic spectrum. Doripenem Monohydrate is used commonly for the treatment of complicated intra-abdominal infections and complicated urinary tract infections.
CAS Number: 364622-82-2
Molecular Weight: 438.52
Related CAS Number:
148016-81-3 (Doripenem free base)
Chemical Name: (4S, 5R, 6R)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-3-(((3S, 5R)-5-((sulfamoylamino)methyl)pyrrolidin-3-yl)thio)-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid hydrate
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Solubility: DMSO: 36 mg/mL(82.09 mM). Water: 26 mg/mL(59.29 mM).
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
How to use
Doripenem is active against Aeromonas (MIC50, 0.03 mg/L), Bacillus spp. (MIC50, 0.03 mg/L) and all tested anaerobic species (MIC range, 32 mg/L) and Enterococcus faecium (MIC90, >32 mg/L) among the enterococcal species. Doripenem is the most active carbapenem (MIC90, 1 to 4 mg/mL) against penicillin-resistant streptococci. Doripenem is found to be highly active against oxacillin-susceptible Staphylococcus aureus and coagulase-negative staphylococci (2705 and 297 isolates, respectively; MIC90s 0.06 mg/L), with a potency greater than that of other carbapenem antibiotics. Doripenem is among the most potent agents tested against Streptococcus pneumoniae, viridans group streptococci and beta-haemolytic streptococci (885, 140 and 397 isolates; MIC(90)s 0.5, 0.5 and 0.03 mg/L, respectively). Doripenem is also active against Citrobacter spp., Enterobacter spp. and Serratia spp. (MIC90s 0.06-0.25 mg/L), including ceftazidime-resistant isolates. Doripenem is slightly more potent (MIC50 2 mg/L) than ertapenem and imipenem (MIC50 4 mg/L), and has a potency similar to that of meropenem (MIC50 2 mg/L), against Burkholderia cepacia (20 isolates). Doripenem demonstrates in vitro activity similar to that of meropenem against gram-negative pathogens and to that of imipenem against gram-positive pathogens.
- Jones RN, et al. J Antimicrob Chemother, 2004, 54(1), 144-154.
- Jones RN, et al. Antimicrob Agents Chemother, 2004, 48(8), 3136-3140.
- Fritsche TR, et al. Clin Microbiol Infect, 2005, 11(12), 974-984.
- Ge Y, et al. Antimicrob Agents Chemother, 2004, 48(4), 1384-13
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.